Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer

Background: We conducted a phase II study by combining FOLFOX4 plus bevacizumab (BV) with erlotinib (ER) as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC). Methods: Patients were divided into two groups in randomized double-blind manner. One group was given FOLFOX4 pl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Am J Cancer Res
Hauptverfasser: Shi, Sha, Lu, Kemei, Gao, Hui, Sun, Huidong, Li, Senlin
Format: Artigo
Sprache:Inglês
Veröffentlicht: e-Century Publishing Corporation 2017
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622230/
https://ncbi.nlm.nih.gov/pubmed/28979818
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge